[go: up one dir, main page]

PE20070354A1 - Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6- - Google Patents

Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6-

Info

Publication number
PE20070354A1
PE20070354A1 PE2006000984A PE2006000984A PE20070354A1 PE 20070354 A1 PE20070354 A1 PE 20070354A1 PE 2006000984 A PE2006000984 A PE 2006000984A PE 2006000984 A PE2006000984 A PE 2006000984A PE 20070354 A1 PE20070354 A1 PE 20070354A1
Authority
PE
Peru
Prior art keywords
alkyl
indazol
cycloalkyl
halogen
amine
Prior art date
Application number
PE2006000984A
Other languages
English (en)
Inventor
Hassan Mahmoud Elokdah
Alexander Alexei Greenfield
Kevin Liu
Robert Emmett Mcdevitt
Geraldine Ruth Mcfarlane
Cristina Grosanu
Jennifer Rebecca Lo
Yanfang Li
Albert Jean Robichaud
Ronald Charles Bernotas
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20070354A1 publication Critical patent/PE20070354A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE X ES O, S, CH2, CO, ENTRE OTROS; n ES 0-6; R1 ES H, ALQUILO C1-C10, CICLOALQUILO C3-C10, ARILO, HETEROARILO, ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS; R2 ES ALQUILO C1-C10, CICLOALQUILO C3-C10, ARILO, ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS CON OH, CN, HALOGENO, ENTRE OTROS; R3 Y R4 SON CADA UNO H, ALQUILO C1-C10 OPCIONALMENTE SUSTITUIDO CON OH, CN, HALOGENO, ENTRE OTROS; R5 Y R6 SON CADA UNO H, ALQUILO C1-C10, ALQUENILO C2-C8, CICLOALQUILO C3-C10, ENTRE OTROS; R7 ES H, HALOGENO, CN, ALQUINILO, ENTRE OTROS; m ES 1-3. SON COMPUESTOS PREFERIDOS: N,N-DIMETIL-3-{[3-(1-NAFTILSULFONIL)-1H-INDAZOL-5-IL]OXI}PROPAN-1-AMINA; N-METIL-N-{2-[3-(FENILSULFONIL)-1H-INDAZOL-5-IL]ETIL}AMINA; N,N-DIMETIL-N-{2-[3-(FENILSULFONIL)-1H-INDAZOL-5-IL]ETIL}AMINA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON LIGANDOS DEL RECEPTOR 5-HIDROXITRIPTAMINA (5-HT6) SIENDO UTILES EN EL TRATAMIENTO DE TRASTORNO DE APRENDIZAJE, SINDROME DE DOWN, AUTISMO, APOPLEJIA, TRAUMA CRANEAL
PE2006000984A 2005-08-15 2006-08-14 Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6- PE20070354A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70831505P 2005-08-15 2005-08-15

Publications (1)

Publication Number Publication Date
PE20070354A1 true PE20070354A1 (es) 2007-04-04

Family

ID=37668440

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000984A PE20070354A1 (es) 2005-08-15 2006-08-14 Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6-

Country Status (21)

Country Link
US (1) US7723329B2 (es)
EP (1) EP1931640A2 (es)
JP (1) JP5146766B2 (es)
KR (1) KR20080039994A (es)
CN (1) CN101282938A (es)
AR (1) AR057756A1 (es)
AU (1) AU2006280091A1 (es)
BR (1) BRPI0614343A2 (es)
CA (1) CA2619010C (es)
CR (1) CR9734A (es)
EC (1) ECSP088189A (es)
GT (1) GT200600376A (es)
IL (1) IL189476A0 (es)
NO (1) NO20080937L (es)
NZ (1) NZ565872A (es)
PE (1) PE20070354A1 (es)
RU (1) RU2429231C2 (es)
SA (1) SA06270314B1 (es)
TW (1) TW200740766A (es)
UA (1) UA94053C2 (es)
WO (1) WO2007021711A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20071143A1 (es) * 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
EP1973876A2 (en) * 2006-01-13 2008-10-01 Wyeth Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors
AU2007238898A1 (en) * 2006-04-12 2007-10-25 Wyeth Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands
WO2007120599A2 (en) * 2006-04-12 2007-10-25 Wyeth Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
US20090012308A1 (en) * 2007-06-13 2009-01-08 Wyeth Process for the manufacture of benzylsulfonylarenes
CN103102322B (zh) * 2011-11-14 2016-02-24 上海交通大学 噁唑类化合物及其制备方法、药物组合物及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001521926A (ja) * 1997-11-04 2001-11-13 ファイザー・プロダクツ・インク 治療上活性の化合物におけるカテコールのインダゾール生物学的等価物置換
AU5960300A (en) * 1999-07-15 2001-02-05 Nps Allelix Corp. Heterocyclic compounds for the treatment of migraine
WO2002036562A2 (en) * 2000-11-02 2002-05-10 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
BR0116323A (pt) * 2000-12-22 2003-10-14 Wyeth Corp Compostos de heterociclilindazol e -azaindazol como ligandos de 5-hidroxitriptamina-6
KR20030062440A (ko) * 2000-12-22 2003-07-25 와이어쓰 5-하이드록시트립트아민-6 리간드로서의헤테로사이클릴알킬인돌 또는 헤테로사이클릴아자인돌화합물
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
WO2002085892A1 (en) * 2001-04-20 2002-10-31 Wyeth Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
CA2444036A1 (en) * 2001-04-20 2002-10-31 Yanfang Li Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
CZ20033529A3 (cs) * 2001-06-07 2004-04-14 F. Hoffman-La Roche Ag Nové deriváty indolu s afinitou k receptoru 5-HT6
US7199147B2 (en) * 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
TW200400177A (en) * 2002-06-04 2004-01-01 Wyeth Corp 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
US7943639B2 (en) * 2002-06-20 2011-05-17 Proximagen Limited Compounds
TW200403243A (en) * 2002-07-18 2004-03-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
JP2006505559A (ja) * 2002-10-18 2006-02-16 エフ．ホフマン−ラ　ロシュ　アーゲー ５−ｈｔ６受容体親和性を持つ４−ピペラジニルベンゼンスルホニルインドール
JP4339795B2 (ja) * 2002-12-03 2009-10-07 エフ．ホフマン−ラ ロシュ アーゲー Ｃｎｓ障害の治療のための５−ｈｔ６レセプターリガンドとしてのアミノアルコキシインドール
AU2004213374A1 (en) * 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
CN100482662C (zh) * 2003-02-14 2009-04-29 惠氏公司 作为5-羟基色胺-6配体的杂环基-3-磺酰基氮杂吲哚或-氮杂吲唑衍生物
AU2005219518A1 (en) * 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Indazole derivatives and pharmaceutical compositions containing them
CN101291913A (zh) * 2005-08-15 2008-10-22 惠氏公司 作为5-羟色胺-6配体的吖嗪基-3-磺酰基吲唑衍生物

Also Published As

Publication number Publication date
JP2009504739A (ja) 2009-02-05
CA2619010C (en) 2013-10-01
RU2008105807A (ru) 2009-09-27
AR057756A1 (es) 2007-12-19
NO20080937L (no) 2008-04-30
CA2619010A1 (en) 2007-02-22
WO2007021711A3 (en) 2007-05-03
US7723329B2 (en) 2010-05-25
SA06270314B1 (ar) 2011-07-20
AU2006280091A1 (en) 2007-02-22
BRPI0614343A2 (pt) 2011-03-22
US20070037802A1 (en) 2007-02-15
EP1931640A2 (en) 2008-06-18
TW200740766A (en) 2007-11-01
IL189476A0 (en) 2008-08-07
RU2429231C2 (ru) 2011-09-20
CN101282938A (zh) 2008-10-08
UA94053C2 (ru) 2011-04-11
ECSP088189A (es) 2008-04-28
WO2007021711A2 (en) 2007-02-22
JP5146766B2 (ja) 2013-02-20
NZ565872A (en) 2011-06-30
CR9734A (es) 2008-04-03
KR20080039994A (ko) 2008-05-07
GT200600376A (es) 2007-03-29

Similar Documents

Publication Publication Date Title
PE20110153A1 (es) Derivados de piridazina como inhibidores de smo
PE20081441A1 (es) Subtipo de amidas selectivas de diazabicicloalcanos
PE20120061A1 (es) Derivados de pirimidina como antagonistas del receptor ccr2
PE20080067A1 (es) DERIVADOS DE TRIAZOLOPIRAZINA COMO MODULADORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE HEPATOCITO (c-MET O HGFR)
PE20191495A1 (es) Piridonamidas como moduladores de canales de sodio
PE20140411A1 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20060487A1 (es) Derivados de 2-carbamida-4-feniltiazol como moduladores de la actividad de quimioquinas
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
PE20110408A1 (es) Derivados de benzazepina y sus usos como antagonistas de histamina h3
PE20051046A1 (es) Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
PE20090237A1 (es) Derivados de sulfonamidas como inhibidores de los canales de sodio
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20030039A1 (es) Derivados de indol con afinidad por el receptor 5-ht6
TW200740773A (en) Diaminopyrimidines as P2X3 and P2X2/3 modulators
PE20071245A1 (es) COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs)
PE20060500A1 (es) Derivados de heteroaril sulfamida benzo-fusionada como anticonvulsivantes
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
PE20142452A1 (es) AMIDAS CICLICAS COMO INHIBIDORES DE MetAP-2
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR062409A1 (es) Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto
PE20090622A1 (es) Nuevos derivados de bencimidazol sustituido
PE20071311A1 (es) Compuestos 8-azabiciclo[3.2.1]octano como antagonistas del receptor opioide mu
PE20110833A1 (es) Nuevas octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueantes de los canales de calcio

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed